Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisition

Novo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential.

Revolution Medicines and Tango Therapeutics reported a high response rate in a combined pancreatic cancer regimen, highlighting promising early data.

Incyte announced a $2 billion acquisition of a bleeding-disorder drug, signaling a major bet on blood disease treatments.

Roche entered a partnership with Nurix Therapeutics to develop a BTK-degrading antibody for blood cancers, while Treeline Biosciences announced a reverse merger with Standard BioTools to go public.